表 1. Results of key clinical trials of immunotherapies for advanced hepatocellular carcinoma.
晚期肝癌免疫治疗关键临床试验结果
| Study | Treatment options | Clinical trial stage |
Outcome | |||
| ORR% | mOS | mPFS | Other | |||
| ORR: objective response rate; mPFS: median progression-free survival; mOS: median overall survival; OS: overall survival; mTTP: median time to progression; DCR: disease control rate; mDOR: median duration of response; mTTR: median response time. | ||||||
| CheckMate 040[16] | Nivolumab | Ⅰ/Ⅱ | 20 | 15.6 | 4.0 | |
| KEYNOTE-224[19] | Pembrolizumab | Ⅱ | 17 | 12.9 | 4.9 | |
| Richard, et al[21] | Pembrolizumab + lenvatinib | Ⅰb | 36 | 22 | 8.6 | mTTP 9.7 months |
| IMbrave 150[22] | Atezolizumab + bevacizumab | Ⅲ | 30 | 19.2 | 6.9 | DCR 74%, OS of 12 months 67%, OS of 18 months 52% |
| ORIENT-32[24] | Sintilimab + bevacizumab | Ⅱ/Ⅲ | 25 | 4.6 | ||
| RESCUE[25] | Camrelizumab + Apatinib | Ⅱ | 34.3 | 5.7 |
OS of 9 months 86.7%, OS of 12 months 74.7%, OS of 18 months 58.1%, DCR 77.1%, mDOR 14.8 months |
|
| HIMALAYA[27] | Durvalumab + tremelimumab | Ⅲ | 20.1 | 16.4 | 3.8 | mDOR 22.34 months, mTTR 2.17 months,3-year survival rate 30.7% |